Brugada syndrome is an inherited sudden-death arrhythmia syndrome. Na þ -current dysfunction is central, but mutations in the SCN5A gene (encoding the cardiac Na þ -channel Nav1.5) are present in only 20% of probands.
Introduction
Brugada syndrome, first described in 1992, has a high risk of sudden cardiac death. 1 The syndrome associates a typical ECG pattern (ST-segment elevation in the right precordial leads) with an increased risk of life-threatening ventricular arrhythmias. 2 Inherited as an autosomal dominant trait, Brugada syndrome is associated with mutations in the SCN5A gene encoding the pore-forming a-subunit of the cardiac Na þ -channel (Nav1.5) in about 20% of cases. 3 The diagnosis of Brugada syndrome may be difficult because penetrance is age-dependant, gene-carriers are often asymptomatic, and the ECG pattern can be dynamic or concealed, although pharmacologic challenge can unmask the phenotype.
2 † These authors contributed equally.
Since only a minority of Brugada patients has detectable mutations, we considered alternative disease mechanisms involving a consistent pattern of abnormalities in cardiac conduction and arrhythmogenesis. We specifically hypothesized that a common pattern of cardiac ion-channel and transporter gene-expression might contribute to the pathophysiology of Brugada syndrome, by producing a phenotypic background that facilitates the expression of disease characteristics in the context of appropriate genotypic and/or environmental factors. To test this notion, we applied high-throughput real-time PCR to obtain full profiling of ion-channel subunit expression in right-ventricular septal endomyocardial biopsies from patients with Brugada syndrome, in comparison with results from two control groups and two patient-groups with other types of arrhythmogenic rightventricular disorders.
Methods Samples
All protocols for sample procurement and handling were approved by local institutional research boards and informed consent was obtained. From October 2004 to December 2005, endomyocardial biopsies from 10 unrelated consecutive Brugada-syndrome patients were collected at the Department of Cardiology and Angiology, Hospital of the University of Münster, Germany. The final diagnosis of Brugada syndrome was made following presently accepted standards, including type-I ECGs in all. 2 Patients were genotyped by direct sequencing of all coding exons of the SCN5A gene. 3 A minimum of five endomyocardial biopsies (1 -2 mm 3 ) were collected per patient from the right-ventricular septum, at least 7 days after the last arrhythmic episode to exclude the effects of the acute episode and/or its treatment. Three biopsies were fixed for histology to detect structural heart disease, in particular arrhythmogenic rightventricular cardiomyopathy (ARVC). Histological examination showed non-specific fatty-tissue infiltration in one of the three samples from patient V, mild focal interstitial fibrosis in patient III, and focal interstitial fibrosis with borderline myocyte hypertrophy in adjacent areas in patient IV. Histology was normal in other cases. No patient showed signs of inflammation or ARVC. The remaining samples were immediately frozen in liquid-N 2 and stored at 2808C for research purposes.
Cardiac material from two distinct control groups, both age-and sex-matched to Brugada-syndrome patients, was also used (Supplementary material online, Table SI ). Control group 1 (Ctl-1; 10 males, one female; mean age 39.5 + 3.7 years) consisted of nondiseased endomyocardial tissue from hearts explanted to collect pulmonary and aortic valves for transplant surgery at the University of Szeged, Hungary. Subjects from whom hearts were explanted received no medication except dobutamine, furosemide, and plasma expanders. All experimental protocols for Ctl-1 sample procurement and handling were approved by the Ethical Review Board of the Medical Center of the University of Szeged (No. 51-57/1997 OEJ) and conformed to the Helsinki Declaration of the World Medical Association. 4 Cardiac tissue was stored in cardioplegic solution at 48C for 4-8 h. Endomyocardial slices, 1 mm thick, were carefully cut from the right-sided ventricular septum and frozen in liquid nitrogen. 5 Tissue preservation and dissection procedure in this group differed from Brugada patients, so we included an additional control group (Ctl-2; five males, two females; mean age 37.8 + 2.9 years), from whom biopsies were obtained during routine post-transplantation follow-up (in the absence of any signs of rejection) ,1 month after heart-transplantation in an identical fashion to Brugada-syndrome samples. These control groups allowed us to control for tissue-procurement and handling methods (identical for Brugada and Ctl-2 patients) and to control for potential posttransplant changes (absent in both Brugada and Ctl-1 subjects).
To determine whether the ion-channel expression profile of Brugada patients is different from patients with other forms of rightventricular tachyarrhythmia, we examined endomyocardial samples obtained with the same biopsy-catheter protocol used for Brugada patients and Ctl-2, from 10 patients with ARVC and nine patients with idiopathic right-ventricular outflow-tract tachycardia (RVOT), at the University Hospital in Münster, Germany. The diagnosis was established in all patients by detailed non-invasive and invasive investigations according to established diagnostic criteria. 6 Endomyocardial biopsies in patients with RVOT were obtained within a broader research protocol related to the pathophysiological assessment of patients with inherited ventricular tachyarrhythmias. The protocol was approved by the Institutional Review Board and Ethics Committee of the University Hospital in Münster, Germany.
RNA preparation
Two snap-frozen endomyocardial biopsies per patient were pooled (constituting one sample set) for RNA extraction. Total RNA was isolated using TRIzol (Life Technologies) and DNase treated with the RNeasy Fibrous Tissue Micro Kit (Qiagen). RNA quality was assessed by polyacrylamide-gel micro-electrophoresis (Agilent 2100 Bioanalyzer). Lack of genomic DNA contamination was verified by PCR.
TaqMan real-time reverse-transcriptasepolymerase chain reaction
TaqMan low-density arrays (TLDA; Applied Biosystems) were used in a two-step reverse-transcriptase -polymerase chain reaction (RT -PCR) process, as previously reported. 
Data analysis
Data were analysed independently by two procedures: (i) two-way hierarchical agglomerative clustering was applied to the gene-expression matrix consisting of biopsies and the DCt for each of the 77 electrical-signalling genes. We applied average linkageclustering with uncentred correlation using Cluster software. 10 Clusters were visualized using Treeview software; (ii) gene-expression values in control and right-ventricular disease groups were first compared with the Wilcoxon rank-sum test, followed by the Significance Analysis of Microarrays (SAM version 2023A) 11 to minimize false-positive gene identification by using repeated randomsample permutations. The false-discovery rate was set at 0.5% so that less than 1 out of the 77 analysed genes would be falsely identified per inter-group comparison as differentially expressed. To assess the over or under expression of each gene in the Brugada group, we calculated the variation of gene expression defined as: (absolute gene-expression value minus median gene-expression value in control group)/median control gene-expression value (Â100%).
Results

Clinical characteristics
Ten patients (nine males, one female: mean age 36.4 + 3.3 years) with a clinical diagnosis of Brugada syndrome entered the study ( Table 1) . Seven were symptomatic with cardiac arrest (n ¼ 1), syncope (n ¼ 5), or attacks of dizziness (n ¼ 1). A spontaneous type-1 Brugada ECG was present in all three asymptomatic patients and five symptomatic patients. In the remaining two symptomatic patients, type-1 ECGs were provoked by ajmaline challenge (1 mg/kg i.v.). 12 Ten male patients with ARVC (mean age 48.4 + 3.3 years) and nine patients with idiopathic right-ventricular outflow-tract tachycardia (two males, seven females; mean age 50.4 + 4.6 years) were enrolled ( Table 2) .
Hierarchical clustering
Hierarchical clustering analysis was applied to the 77 genes and 28 samples from Brugada syndrome and control subjects, and grouped samples according to gene-expression similarities, with the most similar expression patterns located closest to each other and the most different furthest apart. For visual appreciation, samples are linked to a tree: the size of tree branches indicates the distance between clusters, larger branch sizes indicating greater cluster-separation ( Figure 1 ). carrying SCN5A-gene mutations (patients II, III, IV, VI, and X) did not cluster separately from the five patients without SCN5A mutation. Five gene clusters discriminated Brugada patients from controls ( Figure 1) . Gene groups A and B had a lower level of expression in Brugada patients vs. controls, whereas a higher level of expression was found for Brugada patients in gene groups C, D, and E. To challenge the specificity of the ion-channel transcriptional signature of Brugada patients, we examined biopsies from patients with right-ventricular tachycardia due to conditions other than Brugada syndrome (Figure 2) . The Brugada patients were grouped on one branch, distinct from ARVC and RVOT patients. Three gene clusters that discriminated Brugada patients are indicated. Gene groups A and B were expressed at a higher level in Brugada patients, whereas the opposite was true for group C. In contrast, the ion-channel expression profile of the ARVC patients intermingled with the RVOT-patient profile (as vs. the both control groups; Supplementary material online, Figure S1 ). Of interest, many of the same gene-expression variations that distinguished Brugada patients from controls also differentiated them from right-ventricular arrhythmia patients.
Differentially expressed genes in Brugada-syndrome tissue
Since we used two distinct control groups and two rightventricular tachyarrhythmia groups, four collections of genes that were differentially expressed in Brugada-syndrome hearts were identified: one reached significance when compared with Ctl-1 (n ¼ 54 genes), one reached significance vs. Ctl-2 (n ¼ 25 genes), one was significant compared with ARVC (n ¼ 33 genes), and the other was significant vs. RVOT (n ¼ 48 genes). Detailed gene-expression values are provided in Supplementary material online, Tables S3A-E. We then focused on the 14 genes that showed consistent differential expression between Brugada patients and each of the four other groups (Ctl-1, Ctl-2, ARVC, and RVOT; Figures 3-5) . As expected, all of the 14 genes are included in the gene clusters that discriminate Brugada patients (Figures 1 and 2) . Brugada-syndrome samples showed consistently lower expression levels of Nav1.5-transcripts, whereas Nav1.3 (a neuronal-type Na þ -channel) and Nav2.1 (a Na þ -channel with unknown function) transcripts had higher expression levels ( Figure 3) . Among the five patients positive for SCN5A, two with a premature protein-truncation (patients III and X) had clearly reduced Nav1.5-transcripts (248% and 241% vs. Ctl-2; 252% and 246% vs. ARVC), whereas the three others (patients II, IV, and VI), all without a premature protein-truncation, had normal Nav1.5 expression (þ10%, 20.1%, and 20.4% vs. Ctl-2; þ2%, 28%, and 28% vs. ARVC). Interestingly, the two patients with Brugada syndrome and reduced Nav1.5-expression exhibited markedly increased Nav1.3-expression (þ62% and þ54% vs. ARVC), whereas the three patients with normal Nav1.5-expression had a smaller increase in Nav1.3 (þ20%, þ20%, and þ5%). Of note, ankyrin-B was not differentially expressed in Brugada- right-ventricular cardiomyopathy (ARVC), biopsies from nine patients with idiopathic right-ventricular outflow-tract tachycardia (RVOT), and biopsies from 10 patients with Brugada syndrome (BrS; horizontally). Same format as in Figure 1 . Three gene-clusters that discriminate Brugada patients from ARVC and RVOT patients are shown on the right (A -C).
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The interindividual variability appears homogenous through the five groups, excepted for TWIK1 and HCN3, which is more variable in Brugada patients than in other groups.
Discussion Major findings
In this first report of systematic transcriptional profiling of Brugada-syndrome patients, their cardiac ion-channel expression pattern was found to be distinct from controls and from patients with other types of right-ventricular tachyarrhythmia. Differences were noted in the expression of Na þ -channels, K þ -channels, and Ca 2þ -channel and homeostasis genes.
Pathophysiological aspects and potential significance
The most commonly accepted construct to explain Brugadasyndrome electrophysiology consists of reduced Na þ -current, which in the face of a large epicardial I to causes loss of epicardial action-potential domes and marked action-potential abbreviation, generating a difference current relative to the normally repolarizing endocardium. 13 Brugada syndrome related to SCN5A dysfunction exhibits conduction anomalies resulting from the deficiency of the major cardiac Na þ -channel, 14 and an alternative explanation of Brugada-syndrome pathophysiology relates it to delayed activation of the right-ventricular outflow tract due to conduction abnormalities. 15 It is unclear why the penetrance of the syndrome Transcriptional profiling in Brugada syndrome is so variable, and why so few Brugada patients have defined Na þ -channel mutations. 15 Our finding of consistent cardiac ion-channel expression patterns in Brugada patients may have pathophysiological significance. It is possible that the occurrence of Brugadasyndrome manifestations requires not only a suitable genetic substrate, but also a distinct background ion-channel expression pattern. Alternatively, a distinct ion-channel expression pattern may be sufficient to produce Brugada-syndrome manifestations, in the face of appropriate electrophysiological modifiers such as dietary, neurohormonal, physical, or other environmental factors. Finally, the ion-channel expression variations that differentiate Brugada patients from the other groups could result from an adaptive phenomenon to a common pathophysiological alteration, resulting from yet unknown primary defects in the non-SCN5A Brugada patients. Our findings could have potential value in developing novel testing for Brugada patients. The identification of distinct transcriptional profiling differences from other populations could eventually lead to molecular diagnostic procedures.
Specific ion-channel variations characteristic of Brugada patients
The reduced Nav1.5-expression characteristic of our Brugada samples may reflect the pathophysiological role suggested by the recognized importance of SCN5A mutations. 13 -15 Nav2.1 (SCN6A or SCN7A) channels were identified for the first time in human hearts, 16 where they are expressed at comparable levels to Nav1.5-channels. 8 This atypical Na þ -channel is only 50% identical to Nav1.x-channels. 17 Attempts to express functional Nav2.1 channels using heterologous expression systems such as Xenopus oocytes, Chinese hamster ovary cells, and human embryonic kidney-293 cells have been unsuccessful, 18, 19 suggesting the requirement of an as-yet unidentified partner. The increased transcript expression of Nav2.1 in Brugada patients could be a compensatory mechanism for the under-expression of Nav1.5. We also observed a dramatic reduction in the expression of Kv4. 
Potential limitations
Because of ethical and practical considerations that limit access to myocardial-tissue samples from patients with rare arrhythmia syndromes, our sample sizes are relatively small. No significant difference was observed in the transcriptional-expression patterns of ion-channel and transporter genes between Brugada patients carrying an SCN5A-gene mutation and patients without an SCN5A-gene mutation. However, we cannot exclude the differences that might have been detected with larger patient-populations. Ion-channel function depends on proper functioning of the expressed gene-product proteins, which we were unable to study because of the small size of our tissue-samples. In addition, tissue-sampling is of necessity limited to the right ventricle, and to an endomyocardial region of the septum. We cannot comment on potential regional differences that could play a significant pathophysiological role. Finally, because of the available patient populations, there were some differences in mean age and sex distribution, particularly for the cardiac-disease groups.
Figure 6
Relative abundance and variability of selected genes in the control and arrhythmogenic groups. The graphs show the relative quantification (y-axis) of genes with statistically significant differential expression in BrS patients vs. Ctl-1, Ctl-2, ARVC, and RVOT groups (x-axis). Data points indicate individual measurements for each patient from Ctl-1 (grey circles), Ctl-2 (empty circles), ARVC (green triangles), RVOT (red triangles), and Brugada (blue squares) groups. Larger circles, triangles, and squares represent the median (+MAD). Data are expressed as ratio vs. HPRT (Â100).
Transcriptional profiling in Brugada syndrome
However, sex differences cannot account for the differences between Brugada and ARVC or Ctl-1/Ctl-2 patients, since these groups were predominantly male. In addition, we have examined sex-based differences in ion-channel subunit expression (unpublished observations) and virtually none of the Brugada-differential genes were identified. With respect to age issues, we have repeated the clustering with ARVC and RVOT patient-subsets agematched to Brugada subjects (Supplementary material online, Figure S2 ) and virtually the same clustering was seen as for the entire groups.
Conclusions
In this study, we applied high-throughput ion-channel transcriptomeanalysis approaches to identify novel pathways potentially involved in the pathophysiology of Brugada syndrome. Our work demonstrates clear differences between patients with Brugada syndrome and controls, and between Brugada syndrome and other rightventricular arrhythmic diseases. Our results provide the first evidence that genomic techniques identify specific expression-profiles in inherited arrhythmia syndromes, with a potential to improve pathophysiological understanding and eventually perhaps molecular diagnostic practice.
Supplementary material
Supplementary material is available at European Heart Journal online.
